BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23465646)

  • 1. 'Silk Road', the virtual drug marketplace: a single case study of user experiences.
    Van Hout MC; Bingham T
    Int J Drug Policy; 2013 Sep; 24(5):385-91. PubMed ID: 23465646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Surfing the Silk Road': a study of users' experiences.
    Van Hout MC; Bingham T
    Int J Drug Policy; 2013 Nov; 24(6):524-9. PubMed ID: 24075939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
    Barratt MJ; Lenton S; Maddox A; Allen M
    Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsible vendors, intelligent consumers: Silk Road, the online revolution in drug trading.
    Van Hout MC; Bingham T
    Int J Drug Policy; 2014 Mar; 25(2):183-9. PubMed ID: 24268875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
    Aldridge J; Askew R
    Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transparency paradox. Building trust, resolving disputes and optimising logistics on conventional and online drugs markets.
    Tzanetakis M; Kamphausen G; Werse B; von Laufenberg R
    Int J Drug Policy; 2016 Sep; 35():58-68. PubMed ID: 26809972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating drug trafficking on the Tor Network: Silk Road 2, the sequel.
    Dolliver DS
    Int J Drug Policy; 2015 Nov; 26(11):1113-23. PubMed ID: 25681266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
    Aldridge J; Décary-Hétu D
    Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States.
    Barratt MJ; Ferris JA; Winstock AR
    Addiction; 2014 May; 109(5):774-83. PubMed ID: 24372954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterising dark net marketplace purchasers in a sample of regular psychostimulant users.
    Van Buskirk J; Roxburgh A; Bruno R; Naicker S; Lenton S; Sutherland R; Whittaker E; Sindicich N; Matthews A; Butler K; Burns L
    Int J Drug Policy; 2016 Sep; 35():32-7. PubMed ID: 26872846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Nice people doing shady things': Drugs and the morality of exchange in the darknet cryptomarkets.
    Masson K; Bancroft A
    Int J Drug Policy; 2018 Aug; 58():78-84. PubMed ID: 29870962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
    Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
    Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
    Tzanetakis M
    Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Going international? Risk taking by cryptomarket drug vendors.
    Décary-Hétu D; Paquet-Clouston M; Aldridge J
    Int J Drug Policy; 2016 Sep; 35():69-76. PubMed ID: 27453145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safer scoring? Cryptomarkets, social supply and drug market violence.
    Barratt MJ; Ferris JA; Winstock AR
    Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
    van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
    J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on Barratt et al. (2014): Steps towards characterizing online anonymous drug marketplace customers.
    Christin N
    Addiction; 2014 May; 109(5):784-5. PubMed ID: 24720826
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-medical use of prescription drugs among illicit drug users: A case study on an online drug forum.
    Rönkä S; Katainen A
    Int J Drug Policy; 2017 Jan; 39():62-68. PubMed ID: 27768995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forensic drug intelligence and the rise of cryptomarkets. Part I: Studying the Australian virtual market.
    Broséus J; Morelato M; Tahtouh M; Roux C
    Forensic Sci Int; 2017 Oct; 279():288-301. PubMed ID: 28927690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.